2013-02-04 14:03:25 -

ORLANDO, February 4, 2013 - Omnicare Specialty Care Group (SCG) has expanded its
service offering for Optimer's DIFICID(®) (fidaxomicin) tablets to include brand
support in addition to specialty pharmacy dispensing services. DIFICID is a
macrolide antibacterial drug indicated in adults 18 years of age and older for
the treatment of Clostridium difficile-associated diarrhea.

Omnicare SCG's specialty pharmacy, Advanced Care Scripts (ACS) supports
Optimer's DIFICID Rx Assist(TM) program, which facilitates a continuum of care
for patients as they transition from the hospital to the home or other setting.


In managing DIFICID Rx Assist, ACS supports an access and reimbursement hotline
and the application process for the Optimer Patient Assistance Program. The new
model also includes support for the DIFICID Co-Pay Assistance Program, which
provides up to $200 toward a commercially insured patient's copayment   obligation
for 1 DIFICID prescription up to 20 tablets per calendar year.  "We are excited
to be working with Optimer in this expanded capacity," said David Hileman,
Senior Vice President of Omnicare Specialty Care Group. "The DIFICID Rx Assist
Program will help address potential issues and challenges encountered in today's
marketplace, including education and access to therapy. Each aspect of the
program is designed to help facilitate the continuum of care for patients."

ACS manages and dispenses specialty medications in multiple disease categories,
including cancer, infectious diseases, auto-immune disorders, multiple sclerosis
and hemophilia. Its expertise across both the specialty and long-term care
channels allows it to provide comprehensive solutions for prescribers and
patients.

About Omnicare Specialty Care Group
Omnicare Specialty Care Group (SCG) is a division of Omnicare, Inc., a Fortune
400 company and provider of comprehensive pharmaceutical services based in
Cincinnati, Ohio. Omnicare SCG is a combination of synergistic tenured companies
with a focused approach to pharmaceutical brand solutions. Together, Omnicare
SCG brings specialists in reimbursement methods, clinicians practiced in
medication therapy management for chronic disease states, and distribution
channel expertise. Solutions are tailored to drive product access by solving
challenges faced by patients and their caregivers, physicians, payers and
manufacturers. Custom programs are led by a single management team across the
organizational platforms, allowing coordination of resources and assets to
support positive outcomes for our patients. For more information, visit
www.omnicarescg.com

About Omnicare
Omnicare, Inc., a Fortune 400 company based in Cincinnati, Ohio, provides
comprehensive pharmaceutical services to patients and providers across North
America.  As the market-leader in professional pharmacy, related consulting and
data management services for skilled nursing, assisted living and other chronic
care institutions, Omnicare leverages its unparalleled clinical insight into the
geriatric market along with some of the industry's most innovative technological
capabilities to the benefit of its long-term care customers.  Omnicare also
provides key commercialization services for the bio-pharmaceutical industry and
end-of-life disease management through its Specialty Care Group.  For more
information, visit  www.omnicare.com/.

Important Safety Information
DIFICID is contraindicated in patients with hypersensitivity to fidaxomicin or
to any of the excipients in the formulation. DIFICID should not be used for
systemic infections. Only use DIFICID for infection proven or strongly suspected
to be caused by C. difficile. Prescribing DIFICID in the absence of a proven or
strongly suspected C. difficile infection is unlikely to provide benefit to the
patient and increases the risk of the development of drug-resistant bacteria.
The most common adverse reactions are nausea (11%), vomiting (7%), abdominal
pain (6%), gastrointestinal hemorrhage (4%), anemia (2%) and neutropenia (2%)

                                     # # #

Contact:

Media:
Ed Loyd
(513) 719-0808
ed.loyd@omnicare.com

Business:
David Hileman
(502) 213-1104
david.hileman@omnicare.com



This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: Omnicare via Thomson Reuters ONE
[HUG#1675140]